What is the treatment of tachycardia-induced cardiomyopathy?
Tachycardia-induced cardiomyopathy (T-CMP) presents with reduced left ventricular systolic function and heart failure symptoms. Prompt, structured management is essential — the primary treatment goal is recovery of ventricular function alongside relief of heart failure symptoms.
Treatment approach
First-line management is built around standard heart failure pharmacotherapy, with neurohormonal blockade as a central component. The complete evidence-based regimen — agent selection, sequencing, and monitoring targets — is detailed in the full protocol.
Clinical goals
Recovery of left ventricular systolic function within 1 to 6 months after appropriate treatment; relief of heart failure symptoms.
References
DOI: 10.4070/kcj.2019.0199
Initial treatment of T-CMP should include standard HF therapy such as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, aldosterone blockers, beta-blockers, and diuretics to attenuate negative remodeling and relieve symptoms related to HF.
In case of improvement, recovery can be achieved within 1 to 6 months after appropriate treatment for tachycardia and HF.